US5820868A
(en)
|
1993-12-09 |
1998-10-13 |
Veterinary Infectious Disease Organization |
Recombinant protein production in bovine adenovirus expression vector system
|
US5846782A
(en)
*
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
US6465253B1
(en)
|
1994-09-08 |
2002-10-15 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
US6127525A
(en)
*
|
1995-02-21 |
2000-10-03 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral coat protein and methods of using same
|
US5770442A
(en)
|
1995-02-21 |
1998-06-23 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral fiber protein and methods of using same
|
DK0833934T4
(da)
*
|
1995-06-15 |
2012-11-19 |
Crucell Holland Bv |
Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6096548A
(en)
|
1996-03-25 |
2000-08-01 |
Maxygen, Inc. |
Method for directing evolution of a virus
|
US6420629B1
(en)
*
|
1996-09-09 |
2002-07-16 |
B.C. Research Inc. |
Process of increasing plant growth and yield and modifying cellulose production in plants
|
FR2758822B1
(fr)
*
|
1997-01-30 |
1999-07-02 |
Centre Nat Rech Scient |
Utilisation d'un polypeptide a titre de recepteur cellulaire des adenovirus
|
US6432699B1
(en)
*
|
1997-03-28 |
2002-08-13 |
New York University |
Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
|
FR2761689B1
(fr)
*
|
1997-04-02 |
1999-06-25 |
Transgene Sa |
Fibre adenovirale modifiee et adenovirus cibles
|
HUP0002070A2
(hu)
*
|
1997-05-28 |
2000-10-28 |
Genvec, Inc. |
Alternatív módon célba juttatott adenovírus
|
CA2294649C
(en)
|
1997-06-23 |
2007-09-25 |
University Of Saskatchewan |
Bovine adenovirus type 3 genome
|
US7297542B2
(en)
*
|
1998-02-06 |
2007-11-20 |
The Uab Research Foundation |
Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
|
US6815200B1
(en)
|
1998-02-17 |
2004-11-09 |
The Uab Research Foundation |
Modified adenovirus containing a fiber replacement protein
|
IL137730A0
(en)
*
|
1998-02-17 |
2001-10-31 |
Uab Research Foundation |
Modified adenovirus containing a fiber replacement protein
|
US20050095231A1
(en)
*
|
1998-02-17 |
2005-05-05 |
Curiel David T. |
Modified adenovirus containing a fiber replacement protein
|
AU4070499A
(en)
|
1998-04-30 |
1999-11-16 |
Cornell Research Foundation Inc. |
Adenoviral vectors with tandem fiber proteins
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
CN1257286C
(zh)
*
|
1998-08-27 |
2006-05-24 |
森泰莱昂公司 |
用于递送异源基因的定向腺病毒载体
|
EP1117767B1
(de)
*
|
1998-09-29 |
2005-11-23 |
The Uab Research Foundation |
Immunmodulation mittels genetischer modifikation von dendritischen zellen und b-zellen
|
US6929946B1
(en)
*
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
US6395875B1
(en)
*
|
1999-01-25 |
2002-05-28 |
Brookhaven Science Associates Llc |
Recombinant soluble adenovirus receptor
|
US7157266B2
(en)
*
|
1999-01-25 |
2007-01-02 |
Brookhaven Science Associates Llc |
Structure of adenovirus bound to cellular receptor car
|
JP2000279178A
(ja)
*
|
1999-02-24 |
2000-10-10 |
Japan Found Cancer Res |
ウイルスベクター
|
US6869936B1
(en)
*
|
1999-03-04 |
2005-03-22 |
Crucell Holland B.V. |
Means and methods for fibroblast-like or macrophage-like cell transduction
|
US6824771B1
(en)
*
|
1999-05-12 |
2004-11-30 |
The Uab Research Foundation |
Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
|
US20040175362A1
(en)
|
1999-05-12 |
2004-09-09 |
Curiel David T. |
Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
|
US6492169B1
(en)
*
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
WO2000076553A1
(en)
*
|
1999-06-11 |
2000-12-21 |
Neurovir Therapeutics, Inc. |
Use of viral vectors and charged molecules for gene therapy
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
EP1124977A1
(de)
*
|
1999-08-27 |
2001-08-22 |
Transgene S.A. |
Modifiziertes fiberprotein des adenovirus und seine verwendungen
|
JP4173663B2
(ja)
*
|
1999-09-17 |
2008-10-29 |
テヘテ ラボラトリーズ,エセ.ア.デ セ.ウベ. |
組換えアデノウイルスベクター、肝臓、腎臓、肺および肥大性の瘢痕の各種の線維症の治療におけるその利用
|
DE60031994T2
(de)
|
1999-09-24 |
2007-09-20 |
The Uab Research Foundation, Birmingham |
Kapsidmodifiziertes rekombinantes Adenovirus und Verfahren zu dessen Anwendung
|
US6955808B2
(en)
*
|
1999-09-24 |
2005-10-18 |
Uab Research Foundation |
Capsid-modified recombinant adenovirus and methods of use
|
WO2001028569A1
(en)
*
|
1999-10-15 |
2001-04-26 |
Canji, Inc. |
Targeted vectors
|
JP2003514577A
(ja)
*
|
1999-11-25 |
2003-04-22 |
トランジェーヌ、ソシエテ、アノニム |
改変アデノウイルス繊維および使用
|
DE60111733T2
(de)
*
|
2000-04-12 |
2006-05-18 |
Amersham Health As |
Integrinbindende peptidderivate
|
US7332337B2
(en)
*
|
2000-05-16 |
2008-02-19 |
Galapagos Nv |
Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
|
EP1157999A1
(de)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
|
AU2001260467A1
(en)
*
|
2000-05-30 |
2001-12-11 |
Ich Productions Limited |
Integrin-targeting vectors having enhanced transfection activity
|
IL153143A0
(en)
*
|
2000-06-02 |
2003-06-24 |
Novartis Ag |
Adenovirus particles with mutagenized fiber proteins
|
US6762031B2
(en)
|
2000-06-16 |
2004-07-13 |
University Of Medicine And Dentistry Of New Jersey |
Targeting viral vectors to specific cells
|
US6524572B1
(en)
*
|
2000-06-26 |
2003-02-25 |
Rainbow Therapeutic Company |
Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
|
US20020164333A1
(en)
*
|
2000-07-10 |
2002-11-07 |
The Scripps Research Institute |
Bifunctional molecules and vectors complexed therewith for targeted gene delivery
|
GB0017720D0
(en)
*
|
2000-07-19 |
2000-09-06 |
Got A Gene Ab |
Modified virus
|
DE60116513T2
(de)
*
|
2000-08-10 |
2006-09-21 |
Crucell Holland B.V. |
Adenovirenvektoren zur transduktion der chondrozyten
|
EP1322774A2
(de)
*
|
2000-09-20 |
2003-07-02 |
Crucell Holland B.V. |
Transduktion von dendritischen zellen durch verwendung der adenovirenvektoren
|
EP1191104A1
(de)
*
|
2000-09-26 |
2002-03-27 |
Introgene B.V. |
Genträger und deren Verwendung zur Herstellung von Arzneimitteln und/oder Impfstöffen
|
US7235233B2
(en)
*
|
2000-09-26 |
2007-06-26 |
Crucell Holland B.V. |
Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
|
NO20004795D0
(no)
*
|
2000-09-26 |
2000-09-26 |
Nycomed Imaging As |
Peptidbaserte forbindelser
|
US6573092B1
(en)
|
2000-10-10 |
2003-06-03 |
Genvec, Inc. |
Method of preparing a eukaryotic viral vector
|
US20030202963A1
(en)
*
|
2000-10-12 |
2003-10-30 |
Cornell Research Foundation, Inc. |
Method of treating cancer
|
MXPA00011713A
(es)
*
|
2000-11-28 |
2002-05-31 |
Tgt Lab S A De C V |
Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
|
AU2002250081A1
(en)
*
|
2001-02-14 |
2002-08-28 |
Uab Research Foundation |
Combined transductional and transcriptional targeting system for improved gene delivery
|
US20030138405A1
(en)
*
|
2001-04-17 |
2003-07-24 |
Juan Fueyo |
Conditionally replicative adenovirus to target the Rb and Rb-related pathways
|
HU230901B1
(hu)
*
|
2001-07-10 |
2019-01-28 |
Ge Healthcare Limited |
Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények
|
US20060275262A1
(en)
*
|
2001-07-26 |
2006-12-07 |
Mathis James M |
Conditionally replicating viruses and methods for cancer virotherapy
|
WO2003062400A2
(en)
*
|
2002-01-24 |
2003-07-31 |
The Scripps Research Institute |
Fiber shaft modifications for efficient targeting
|
ATE447037T1
(de)
*
|
2002-04-25 |
2009-11-15 |
Crucell Holland Bv |
Mittel und verfahren zur herstellung von adenovirusvektoren
|
US20030206916A1
(en)
*
|
2002-05-03 |
2003-11-06 |
Rush-Presbyterian-St. Luke's Medical Center |
Immunogenic peptides
|
CN1548537B
(zh)
*
|
2002-12-27 |
2010-05-05 |
深圳市源兴生物医药科技有限公司 |
疫苗制备方法和抗肿瘤疫苗
|
US20040166091A1
(en)
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
US20070212675A1
(en)
*
|
2003-04-15 |
2007-09-13 |
Novartis Ag |
Flap Endonuclease (Fen1) Regulatory Sequences And Uses Thereof
|
US20070275915A1
(en)
*
|
2003-04-15 |
2007-11-29 |
Cell Genesys, Inc. |
Tmprss2 Regulatory Sequences and Uses Thereof
|
JP2007503843A
(ja)
|
2003-05-14 |
2007-03-01 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
アデノウイルス親和性の拡大
|
US7291498B2
(en)
*
|
2003-06-20 |
2007-11-06 |
The Trustees Of The University Of Pennsylvania |
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
|
WO2005001103A2
(en)
*
|
2003-06-20 |
2005-01-06 |
The Trustees Of The University Of Pennsylvania |
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
|
WO2005012537A2
(en)
*
|
2003-07-25 |
2005-02-10 |
Genvec, Inc. |
Adenoviral vector-based vaccines
|
US7519698B2
(en)
*
|
2003-09-26 |
2009-04-14 |
Ricoh Co., Ltd. |
Method and system for extracting information from networked devices in a multi-protocol remote monitoring system
|
ES2340038T3
(es)
|
2003-11-14 |
2010-05-28 |
Genvec, Inc. |
Composicion farmaceutica para tratar cancer de pancreas localmente avanzado (cpla) no extirpable.
|
EP1718738A2
(de)
*
|
2004-02-23 |
2006-11-08 |
Crucell Holland B.V. |
Verfahren zur reinigung von viren
|
WO2005086922A2
(en)
*
|
2004-03-10 |
2005-09-22 |
Board Of Regents, University Of Texas System |
Oncolytic adenovirus armed with therapeutic genes
|
US7473418B2
(en)
|
2004-03-25 |
2009-01-06 |
Cell Genesys, Inc. |
Pan cancer oncolytic vectors and methods of use thereof
|
JP2007532656A
(ja)
|
2004-04-12 |
2007-11-15 |
アメリカ合衆国 |
アデノウイルスベクターを用いて免疫応答を誘導するための方法
|
JP2008500364A
(ja)
|
2004-05-25 |
2008-01-10 |
キメラコア, インコーポレイテッド |
自己集合性ナノ粒子薬物送達システム
|
US20060062764A1
(en)
*
|
2004-08-25 |
2006-03-23 |
Seshidar-Reddy Police |
Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
|
WO2006039045A2
(en)
*
|
2004-09-01 |
2006-04-13 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adenoviral vectors able to transduce apcs, potential use in immune response generation
|
US20060057127A1
(en)
*
|
2004-09-10 |
2006-03-16 |
Pocheng Liu |
Cytokine-expressing cellular vaccines for treatment of prostate cancer
|
JP2008515908A
(ja)
|
2004-10-06 |
2008-05-15 |
ユニバーシティー オブ ロチェスター |
組織因子経路を阻害する薬剤を使用する、肺高血圧症の治療
|
WO2006050211A2
(en)
|
2004-10-28 |
2006-05-11 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
|
WO2006069203A2
(en)
*
|
2004-12-22 |
2006-06-29 |
California Institute Of Technology |
Methods for proteomic profiling using non-natural amino acids
|
EP1856526A4
(de)
|
2005-01-20 |
2008-11-12 |
Univ Rochester |
Mit thioredoxin interagierendes protein (txnip) als regulator der gefässfunktion
|
US20060205080A1
(en)
*
|
2005-03-01 |
2006-09-14 |
David Frey |
Formulations for therapeutic viruses having enhanced storage stability
|
ATE412737T1
(de)
*
|
2005-04-11 |
2008-11-15 |
Crucell Holland Bv |
Virusreinigung mit ultrafiltration
|
US20060234347A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Harding Thomas C |
Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
|
US20060275812A1
(en)
*
|
2005-06-01 |
2006-12-07 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Assay for agonists and antagonists of ion channels and for regulators of genetic expression
|
WO2006132925A2
(en)
*
|
2005-06-01 |
2006-12-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
|
US20070053934A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Neville Kallenbach |
Polyvalent multimeric composition containing active polypeptides, pharmaceutical compositions and methods of using the same
|
US9651543B2
(en)
|
2005-08-31 |
2017-05-16 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
US8450055B2
(en)
*
|
2005-08-31 |
2013-05-28 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
CA2620495A1
(en)
*
|
2005-08-31 |
2007-03-08 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
CA2629163C
(en)
*
|
2005-11-10 |
2017-03-21 |
Genvec, Inc. |
Adenoviral vector-based foot-and-mouth disease vaccine
|
EP1996716B1
(de)
|
2006-03-20 |
2011-05-11 |
The Regents of the University of California |
Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
|
US8518105B2
(en)
*
|
2006-03-24 |
2013-08-27 |
Abbott Cardiovascular System Inc. |
Methods and apparatuses for coating a lesion
|
US9868961B2
(en)
|
2006-03-30 |
2018-01-16 |
The Regents Of The University Of California |
Methods and compositions for localized secretion of anti-CTLA-4 antibodies
|
US7919079B2
(en)
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
WO2008108776A1
(en)
|
2006-04-07 |
2008-09-12 |
Chimeros, Inc. |
Compositions and methods for treating b- cell malignancies
|
US20080248060A1
(en)
*
|
2007-01-09 |
2008-10-09 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
ES2322637B1
(es)
*
|
2007-06-26 |
2010-03-05 |
Universidad Del Pais Vasco |
Microparticulas de alginato modificado con rgd como sistema de liberacion de farmacos.
|
JP5548616B2
(ja)
|
2007-08-08 |
2014-07-16 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
Vegfr−1/nrp−1標的化ペプチド
|
WO2009032949A2
(en)
|
2007-09-04 |
2009-03-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
US20090202492A1
(en)
*
|
2008-01-25 |
2009-08-13 |
University Of South Florida |
Adenovirus vaccine utilizing ikk as adjuvant
|
CA2742474C
(en)
*
|
2008-11-03 |
2016-05-31 |
Crucell Holland B.V. |
Method for the production of adenoviral vectors
|
US20110256055A1
(en)
|
2008-12-23 |
2011-10-20 |
Ge Healthcare Limited |
Application of 99mtc peptide-based compound as a bone marrow imaging agent
|
WO2010107991A2
(en)
|
2009-03-18 |
2010-09-23 |
Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
|
WO2010120874A2
(en)
|
2009-04-14 |
2010-10-21 |
Chimeros, Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
WO2010144711A2
(en)
|
2009-06-10 |
2010-12-16 |
New York University |
Immunological targeting of pathological tau proteins
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
MX2012004222A
(es)
|
2009-10-15 |
2012-06-08 |
Crucell Holland Bv |
Metodo para purificacion de particulas de adenovirus.
|
AU2010305768B2
(en)
|
2009-10-15 |
2015-05-14 |
Crucell Holland B.V. |
Process for adenovirus purification from high cell density cultures
|
US20120219583A1
(en)
|
2009-10-16 |
2012-08-30 |
Los Alamos National Security, Llc |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
EP2498791B1
(de)
|
2009-11-09 |
2014-12-24 |
GenVec, Inc. |
Methoden zur herstellung von affen-adenovirus vektoren
|
AU2011214262B2
(en)
|
2010-02-15 |
2015-05-21 |
Crucell Holland B.V. |
Method for the production of Ad26 adenoviral vectors
|
WO2011119773A1
(en)
|
2010-03-23 |
2011-09-29 |
Roeth Jeremiah F |
Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
AP3390A
(en)
|
2010-09-20 |
2015-08-31 |
Crucell Holland Bv |
Therapeutic vaccination against active tuberculosis
|
BR112013004582A2
(pt)
|
2010-09-27 |
2016-09-06 |
Crucell Holland Bv |
método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
WO2012088041A1
(en)
|
2010-12-20 |
2012-06-28 |
Genvec, Inc. |
Adenoviral vector-based dengue fever vaccine
|
EP2658567A4
(de)
|
2010-12-28 |
2014-09-24 |
Univ Rochester |
Verfahren zur modifikation einer insulinsignalübertragung mittels biliverdinreduktase (bvr) und bvr-abgeleiteten peptiden
|
CN103534355A
(zh)
|
2011-03-04 |
2014-01-22 |
英特瑞克斯顿股份有限公司 |
条件性表达蛋白质的载体
|
HUE051021T2
(hu)
|
2011-09-07 |
2021-01-28 |
Sinai School Medicine |
Ceramidáz és sejtek differenciálódása
|
JP2014527072A
(ja)
|
2011-09-09 |
2014-10-09 |
バイオメド リアルティー, エル.ピー. |
ウイルスタンパク質の集合を制御するための方法および組成物
|
WO2013074501A1
(en)
|
2011-11-14 |
2013-05-23 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
SG11201404313YA
(en)
|
2012-01-25 |
2014-10-30 |
Dnatrix Inc |
Biomarkers and combination therapies using oncolytic virus and immunomodulation
|
BR112014019049A2
(pt)
|
2012-02-02 |
2017-07-04 |
Univ Texas |
adenovirus imunogênico
|
KR102063195B1
(ko)
|
2012-02-07 |
2020-01-07 |
글로벌 바이오 테라퓨틱스, 인크. |
핵산 전달의 구획화된 방법 및 이의 조성물 및 용도
|
AU2013231423B2
(en)
|
2012-03-12 |
2018-10-04 |
Janssen Vaccines & Prevention B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
US9119813B2
(en)
|
2012-03-22 |
2015-09-01 |
Crucell Holland B.V. |
Vaccine against RSV
|
AP2014007993A0
(en)
|
2012-03-22 |
2014-10-31 |
Crucell Holland Bv |
Vaccine against RSV
|
EP2855669B1
(de)
|
2012-05-29 |
2018-10-10 |
GenVec, Inc. |
Modifizierte serotyp-28-adenovirusvektoren
|
US9694050B2
(en)
|
2012-10-21 |
2017-07-04 |
University Of Rochester |
THY1 (CD90) as a novel therapy to control adipose tissue accumulation
|
AU2014236207B2
(en)
|
2013-03-14 |
2019-05-23 |
Salk Institute For Biological Studies |
Oncolytic adenovirus compositions
|
EP2992112B1
(de)
|
2013-04-22 |
2020-06-03 |
Icahn School of Medicine at Mount Sinai |
Mutationen in pdgfrb und notch3 als ursachen für autosomale dominante infantile myofibromatose
|
PL2988780T3
(pl)
|
2013-04-25 |
2019-06-28 |
Janssen Vaccines & Prevention B.V. |
Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
|
WO2014202570A1
(en)
|
2013-06-17 |
2014-12-24 |
Crucell Holland B.V. |
Stabilized soluble pre-fusion rsv f polypeptides
|
JP6293892B2
(ja)
|
2013-08-08 |
2018-03-14 |
グローバル・バイオ・セラピューティクス・インコーポレイテッドGlobal Bio Therapeutics,Inc. |
低侵襲処置用インジェクションデバイスおよびその使用
|
US11364032B2
(en)
|
2013-08-08 |
2022-06-21 |
Global Bio Therapeutics, Inc. |
Clamp device for minimally invasive procedures and uses thereof
|
CA2923352C
(en)
|
2013-09-19 |
2022-05-03 |
Crucell Holland B.V. |
Stable adenovirus formulations
|
MX2017002931A
(es)
|
2014-09-07 |
2017-05-30 |
Selecta Biosciences Inc |
Metodos y composiciones para atenuar respuestas inmunes anti-vector de transferencia viral.
|
TWI710635B
(zh)
|
2014-10-09 |
2020-11-21 |
美商珍維克公司 |
編碼人類無調同源物-1(hath1)之腺病毒載體
|
RS58080B1
(sr)
|
2014-11-04 |
2019-02-28 |
Janssen Vaccines & Prevention Bv |
Terapeutske vakcine protiv hpv16
|
HUE051897T2
(hu)
|
2015-03-18 |
2021-03-29 |
Janssen Vaccines & Prevention Bv |
Vizsgálatok rekombináns expressziós rendszerekre
|
CN107466324B
(zh)
|
2015-04-14 |
2022-01-14 |
扬森疫苗与预防公司 |
具有双向启动子的表达两种转基因的重组腺病毒
|
US10457708B2
(en)
|
2015-07-07 |
2019-10-29 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F polypeptides
|
KR102638978B1
(ko)
|
2015-07-07 |
2024-02-22 |
얀센 백신스 앤드 프리벤션 비.브이. |
Rsv에 대한 백신
|
BR112018003019A2
(pt)
|
2015-08-20 |
2018-09-25 |
Janssen Vaccines & Prevention Bv |
vacinas terapêuticas contra hpv18
|
CA3001050C
(en)
|
2015-10-06 |
2023-03-28 |
Janssen Vaccines & Prevention B.V. |
Method for preventing surface-induced degradation of viruses using cyclodextrins
|
WO2017079442A1
(en)
|
2015-11-04 |
2017-05-11 |
Icahn School Of Medicine At Mount Sinai |
Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
|
CA3013639A1
(en)
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
|
WO2017147265A1
(en)
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
High throughput assay for measuring adenovirus replication kinetics
|
KR102506895B1
(ko)
|
2016-04-05 |
2023-03-08 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 용해성 융합-전 rsv f 단백질
|
CA3018139A1
(en)
|
2016-04-05 |
2017-10-12 |
Janssen Vaccines & Prevention B.V. |
Vaccine against rsv
|
US11246868B2
(en)
|
2016-04-26 |
2022-02-15 |
Icahn School Of Medicine At Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
WO2017192418A1
(en)
|
2016-05-02 |
2017-11-09 |
Janssen Vaccine & Prevention B.V. |
Therapeutic hpv vaccine combinations
|
US11473105B2
(en)
|
2016-05-12 |
2022-10-18 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
KR102421049B1
(ko)
|
2016-05-30 |
2022-07-15 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 융합-전 rsv f 단백질
|
CN109312362B
(zh)
|
2016-06-20 |
2022-06-28 |
扬森疫苗与预防公司 |
有效和平衡的双向启动子
|
US10744196B2
(en)
|
2016-07-14 |
2020-08-18 |
Janssen Vaccines & Prevention B.V. |
HPV vaccines
|
MA45996A
(fr)
|
2016-08-16 |
2021-06-02 |
Bluebird Bio Inc |
Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
|
WO2018039333A1
(en)
|
2016-08-23 |
2018-03-01 |
Bluebird Bio, Inc. |
Tim3 homing endonuclease variants, compositions, and methods of use
|
CN109923211A
(zh)
|
2016-09-08 |
2019-06-21 |
蓝鸟生物公司 |
Pd-1归巢核酸内切酶变体、组合物及使用方法
|
CA3038968A1
(en)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into t cells
|
CN110050066A
(zh)
|
2016-10-17 |
2019-07-23 |
蓝鸟生物公司 |
TGFβR2核酸内切酶变体、组合物和使用方法
|
KR20240046620A
(ko)
|
2016-11-17 |
2024-04-09 |
2세븐티 바이오, 인코포레이티드 |
TGFβ 신호 컨버터
|
CA3045892A1
(en)
|
2016-12-12 |
2018-06-21 |
Salk Institute For Biological Studies |
Tumor-targeting synthetic adenoviruses and uses thereof
|
JP2020506890A
(ja)
|
2017-01-07 |
2020-03-05 |
セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. |
合成ナノキャリアにカップリングした免疫抑制剤のパターン化された投与
|
US11034978B2
(en)
|
2017-02-09 |
2021-06-15 |
Janssen Vaccines & Prevention B.V. |
Potent and short promoter for expression of heterologous genes
|
CN110446781A
(zh)
|
2017-02-15 |
2019-11-12 |
蓝鸟生物公司 |
供体修复模板多重基因组编辑
|
US11566045B2
(en)
*
|
2017-03-14 |
2023-01-31 |
Zhejiang Fonow Medicine Co., Ltd |
Tumor targeting polypeptide and method of use thereof
|
SG11201908280SA
(en)
|
2017-03-30 |
2019-10-30 |
Univ Queensland |
"chimeric molecules and uses thereof"
|
CA3061278A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
EP3630962A4
(de)
|
2017-05-25 |
2021-01-20 |
Bluebird Bio, Inc. |
Cblb-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung
|
KR20200053518A
(ko)
|
2017-09-15 |
2020-05-18 |
얀센 백신스 앤드 프리벤션 비.브이. |
Rsv에 대한 면역의 안전한 유도를 위한 방법
|
WO2019070974A1
(en)
|
2017-10-04 |
2019-04-11 |
Bluebird Bio, Inc. |
PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
|
WO2019075360A1
(en)
|
2017-10-13 |
2019-04-18 |
Selecta Biosciences, Inc. |
METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES
|
MA50502A
(fr)
|
2017-10-31 |
2020-09-09 |
Janssen Vaccines & Prevention Bv |
Adénovirus et utilisations associées
|
KR20200083510A
(ko)
|
2017-10-31 |
2020-07-08 |
얀센 백신스 앤드 프리벤션 비.브이. |
아데노바이러스 및 이의 용도
|
EA202091074A1
(ru)
|
2017-10-31 |
2020-07-22 |
Янссен Вэксинс Энд Превеншн Б.В. |
Аденовирус и его применения
|
SG11202003398SA
(en)
|
2017-10-31 |
2020-05-28 |
Janssen Vaccines & Prevention Bv |
Adenovirus vectors and uses thereof
|
IL294797B2
(en)
|
2018-01-23 |
2024-06-01 |
Janssen Vaccines Prevention B V |
Influenza virus vaccines and their uses
|
AU2019225251A1
(en)
|
2018-02-26 |
2020-10-15 |
AnTolRx, Inc. |
Tolerogenic liposomes and methods of use thereof
|
SG11202008687XA
(en)
*
|
2018-03-16 |
2020-10-29 |
Res Inst Nationwide Childrens Hospital |
Increasing tissue specific gene delivery by capsid modification
|
US12060419B2
(en)
|
2018-06-14 |
2024-08-13 |
Regeneron Pharmaceuticals, Inc. |
CD79A chimeric antigen receptors
|
WO2020072059A1
(en)
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
JOP20210186A1
(ar)
|
2019-01-10 |
2023-01-30 |
Janssen Biotech Inc |
مستضدات البروستاتا المستحدثة واستخداماتها
|
JP2022521268A
(ja)
|
2019-02-21 |
2022-04-06 |
アンリーシュ イミュノ オンカリティクス,インコーポレイテッド |
腫瘍溶解性アデノウイルスベクター及び使用法
|
US20220204567A1
(en)
|
2019-04-25 |
2022-06-30 |
Janssen Vaccines & Prevention B.V. |
Recombinant influenza antigens
|
BR112021021566A2
(pt)
|
2019-04-28 |
2022-04-19 |
Selecta Biosciences Inc |
Métodos para tratamento de indivíduos com imunidade preexistente a vetores de transferência viral
|
EP3969044A1
(de)
|
2019-05-15 |
2022-03-23 |
Janssen Vaccines & Prevention B.V. |
Gleichzeitige verabreichung eines saisonalen grippeimpfstoffs und eines adenovirus-basierten impfstoffs gegen das respiratorische synzytialvirus
|
MX2021013947A
(es)
|
2019-05-15 |
2021-12-14 |
Janssen Vaccines & Prevention Bv |
Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus.
|
CA3141863A1
(en)
|
2019-05-28 |
2020-12-03 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuated anti-viral transfer vector immune response
|
EP4025247A1
(de)
|
2019-09-05 |
2022-07-13 |
Janssen Vaccines & Prevention B.V. |
Influenzavirusimpfstoffe und verwendungen davon
|
CA3156471A1
(en)
|
2019-10-03 |
2021-04-08 |
Janssen Vaccines & Prevention B.V. |
ADENOVIRUS VECTORS AND THEIR USES
|
WO2021072129A2
(en)
|
2019-10-08 |
2021-04-15 |
Trustees Of Boston College |
Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
|
US12018289B2
(en)
|
2019-11-18 |
2024-06-25 |
Janssen Biotech, Inc. |
Vaccines based on mutant CALR and JAK2 and their uses
|
EP4073102A4
(de)
|
2019-12-12 |
2024-05-08 |
Ting Therapeutics LLC |
Zusammensetzungen und verfahren zur prävention und behandlung von gehörverlust
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
CA3170369A1
(en)
|
2020-03-05 |
2022-04-14 |
Michal Shahar |
Methods and compositions for treating cancer with immune cells
|
WO2021207636A2
(en)
|
2020-04-10 |
2021-10-14 |
Sola Biosciences Llc |
Compositions and methods for the treatment of protein aggregation disorders
|
US20210315986A1
(en)
|
2020-04-13 |
2021-10-14 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
EP4143215A2
(de)
|
2020-04-28 |
2023-03-08 |
SOLA Biosciences LLC |
Zusammensetzungen und verfahren zur behandlung von tdp-43-proteinopathien
|
JP2023529371A
(ja)
|
2020-06-05 |
2023-07-10 |
ソラ・バイオサイエンシズ・エルエルシー |
シヌクレイノパチーの処置のための組成物および方法
|
JP2023529892A
(ja)
|
2020-06-09 |
2023-07-12 |
イノザイム ファーマ インク. |
可溶性enpp1又はenpp3タンパク質及びその使用
|
EP4176087A1
(de)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Verfahren zur bestimmung des ansprechens auf eine prostatakrebsbehandlung
|
EP4175721A1
(de)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostata-neoantigene und ihre verwendungen
|
US20230029453A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
CA3199433A1
(en)
|
2020-10-26 |
2022-05-05 |
Sola Biosciences Llc |
Compositions and methods for the treatment of alzheimer's disease
|
CA3225252A1
(en)
|
2021-07-14 |
2023-01-19 |
Jordan JARJOUR |
Engineered t cell receptors fused to binding domains from antibodies
|
EP4413024A2
(de)
|
2021-10-08 |
2024-08-14 |
SOLA Biosciences LLC |
Zusammensetzungen und verfahren zur behandlung von proteopathien
|
JP2024537178A
(ja)
|
2021-10-08 |
2024-10-10 |
ソラ・バイオサイエンシズ・エルエルシー |
p53媒介性癌の処置のための組成物および方法
|
US20230141563A1
(en)
|
2021-10-12 |
2023-05-11 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
US20230357437A1
(en)
|
2022-03-09 |
2023-11-09 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
WO2023196997A2
(en)
|
2022-04-08 |
2023-10-12 |
2Seventy Bio, Inc. |
Multipartite receptor and signaling complexes
|
EP4338727A1
(de)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Adenovirus-formulierungen
|